This CPB has been revised to state that teriparatide (Bonsity) is considered medically necessary for the same indications as its reference drug, teriparatide (Forteo).  This CPB has been revised to: (i) remove the requirement for trials of other least cost brands of parathyroid hormone analogs as a prerequisite for Forteo, (ii) add dosing recommendations for Bonsity, and (iii) change the title to "Teriparatide". This CPB has been revised to add a precertification requirement note for Forteo.